Sign in
TerminatedPhase 3

ARrest RESpiraTory Failure From PNEUMONIA

Key facts

Who runs it
Stanford University
Where
Baltimore, Birmingham, Gainesville, Jacksonville, New Orleans, New York, Palo Alto, Philadelphia, Rochester, Scottsdale, and Tucson, United StatesSee the 12 sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
465 people enrolled
Started
1 Jun 2020
Ended
22 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Inhaled budesonide and formoterol
  • Inhaled placebo
Record updated
6 August 2026
Why it stopped
Per DSMB's review of interim analysis, the study has reached the pre-specified futility criteria

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients 18 years or older with
  • Severe pneumonia defined as:
  • Hospitalization for acute (defined as ≤ 14 days) onset of symptoms (cough, sputum production, or dyspnea), AND 2. Radiographic evidence of pneumonia by chest radiograph or CT scan, AND 3. One of the following:
  • Evidence of systemic inflammation (temperature < 35◦C or > 38◦C OR WBC > or < upper or lower limits for site OR procalcitonin > 0.5 mcg/L), OR
  • Known current immunosuppression preventing inflammatory response, OR
  • High clinical suspicion of pneumonia with microbiologic confirmation of infection. Microbiologic confirmation will include a positive nasal swab for a known respiratory virus; a sputum culture growing a likely pathogenic organism plus moderate or greater WBCs (not required for immunocompromised patients); or a positive blood culture with a likely pathogenic organism - e.g., ¼ vials with S. Epidermidis would NOT qualify); AND Hypoxemia defined as new requirement for daytime supplemental oxygen with SpO2 < 92% on room air, ≤ 96% on ≥ 2 L/min oxygen, or > 6L/min or non-invasive ventilation regardless of SpO2 at enrollment. Patients admitted with pneumonia but not meeting criteria for hypoxemia will be followed for up to 48 hours from ED admission to enrolling hospital to assess for development of qualifying hypoxemia

Who cannot take part

  • Intubation (or impending intubation) prior to enrollment; Patients receiving HFNC oxygen or NIV prior to enrollment are not excluded
  • A condition requiring inhaled corticosteroids or beta-agonists (patients receiving inhaled beta-agonists in the ED without an established indication will be eligible if treating clinician is willing to discontinue subsequent treatments)
  • Chronic systemic steroid therapy equivalent to >10 mg prednisone
  • COVID-19 positive patients receiving > 6 mg dexamethasone (40 mg prednisone equivalent dose) except for stress dose steroids for septic shock
  • Non-COVID-19 pneumonia patients receiving systemic steroid > 10 mg prednisone except for stress dose steroids for septic shock
  • Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation syndrome
  • Contraindication or allergy to inhaled corticosteroids or beta-agonists
  • Patients with heart rate > 130 bpm, ventricular tachycardia or new supraventricular tachycardia within last 4 hours will be potentially eligible for enrollment after the condition has resolved
  • Patients with K+ < 3.0 will be potentially eligible for enrollment after the condition has resolved
  • Inability to randomize within 48 hours of presentation to enrolling hospital (randomization beyond 24 hours will be limited to patients with persistent hypoxemia defined by an SpO2 < 97% while on > 3L/min O2)
  • Not anticipated to survive > 48 hours or not expected to require > 48 hours of hospitalization
  • Patient not committed to full support other than intubation or resuscitation (i.e., DNR/DNI status allowed)
  • Pregnancy
  • Incarcerated individual
  • Physician refusal of consent to protocol
  • Patient/surrogate refusal of consent to protocol

Where in United States

  • Johns Hopkins University - Main Campus & BayviewBaltimore, United States
  • University of MarylandBaltimore, United States
  • University of Alabama Birmingham - Main & HighlandsBirmingham, United States
  • University of FloridaGainesville, United States
  • Mayo Clinic- JacksonvilleJacksonville, United States
  • Tulane University - Main & BUMCNew Orleans, United States
  • New York University Langone HealthNew York, United States
  • Stanford UniversityPalo Alto, United States
  • Temple UniversityPhiladelphia, United States
  • Mayo Clinic - RochesterRochester, United States
  • Mayo Clinic ScottsdaleScottsdale, United States
  • University of Arizona - Main & South CampusTucson, United States

About the trial

What the trial wants to find out

This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    4 ml aerosolized 0.9% saline every 12 hours x 10 doses

    Treatment: Inhaled placebo

  • InterventionExisting treatment, for comparison

    aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 10 doses

    Treatment: Inhaled budesonide and formoterol

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)
Publications
Record updated
6 August 2026